With the economy sputtering toward recovery, federal outlays shriveling and the political scene in upheaval, the US biotech policy picture is more than a little blurred. Jeffrey L. Fox reports.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Anonymous. A Strategy For American Innovation: Securing Our Economic Growth and Prosperity (National Economic Council, Council of Economic Advisers, and Office of Science and Technology Policy; February 2011). http://www.whitehouse.gov/sites/default/files/uploads/InnovationStrategy.pdf
Anonymous. New Directions: The Ethics of Synthetic Biology and Emerging Technologies (Presidential Commission for the Study of Bioethical Issues, December 2010). http://www.bioethics.gov/documents/synthetic-biology/PCSBI-Synthetic-Biology-Report-12.16.10.pdf
Fox, J.L. Nat. Biotechnol. 29, 91–92 (2011).
Waltz, E. Nat. Biotechnol. 29, 179–181 (2011).
Anonymous. Patent Reform Act of 2011. http://judiciary.senate.gov/legislation/upload/BillText-PatentReformAct.pdf
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fox, J. Mixed messages from Washington. Nat Biotechnol 29, 303–305 (2011). https://doi.org/10.1038/nbt.1836
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.1836
This article is cited by
-
Positive signals from Washington
Nature Biotechnology (2012)
